Page 18 - Read Online

follow-up in small incidental tumors of the pancreas, 14. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn
the optimal approach to NEC G3 tumors with well J, Koch M, Röcken C, Rindi G, Ruszniewski P, Wiedenmann B,
differentiated morphology, liver ablative therapies, and Pape UF. Neuroendocrine tumors of midgut and hindgut origin:
surgery in the context of metastatic disease. tumor-node-metastasis classification determines clinical outcome.
Cancer 2011;117:3332-41.
15. Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Fave GD,
Financial support and sponsorship Falconi M. Systematic review of resection of primary midgut
Nil. carcinoid tumour in patients with unresectable liver metastases. Br
J Surg 2012;99:1480-6.
Conflicts of interest 16. Norlen O, Hessman O, Stålberg P, Akerström G, Hellman P.
There are no conflicts of interest. Prophylactic cholecystectomy in midgut carcinoid patients. World
J Surg 2010;34:1361-7.
REFERENCES 17. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P,
Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder
J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-
1. Bosman FT, Carneiro F, Hruban RH, Theise ND. World Health controlled, double- blind, prospective, randomized study on the
Organization Classification of Tumours. Pathology and Genetics. effect of octreotide LAR in the control of tumor growth in patients
Tumors of the Digestive System. Lyon: IARC Press; 2010. with metastatic neuroendocrine midgut tumors: a report from the
2. Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli PROMID Study Group. J Clin Oncol 2009;27:4656-63.
P, Scarpa A, Falconi M. Tumor size correlates with malignancy in 18. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková
nonfunctioning pancreatic endocrine tumor. Surgery 2011;150:75-82. E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A,
3. Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators.
JL, Levy MJ, Huebner M. Small, nonfunctioning, asymptomatic Lanreotide in metastaticenteropancreatic neuroendocrine tumors. N
pancreatic neuroendocrine tumors (PNETs): role for nonoperative Engl J Med 2014;371:224-33.
management. Surgery 2012;152:965-74. 19. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca
4. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, P, Caracciolo M, Mäcke HR, Chinol M, Paganelli G. Receptor-
Tseng JF. Pancreatic neuroendocrine tumors: the impact of surgical mediated radionuclide therapy with 90Y-DOTATOC in association
resection on survival. Cancer 2009;115:741-51. with amino acid infusion: a phase I study. Eur J Nucl Med Mol
5. Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio Imaging 2003;30:207-16.
V, Bassi C, Di Carlo V, Pederzoli P. Parenchyma-preserving 20. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van
resections for small nonfunctioning pancreatic endocrine tumors. Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP.
Ann Surg Oncol 2010;17:1621-7. Treatment with the radiolabeled somatostatin analog [177 Lu-
6. Crippa S, Zerbi A, Boninsegna L, Capitanio V, Partelli S, Balzano DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin
G, Pederzoli P, Di Carlo V, Falconi M. Surgical management of Oncol 2008;26:2124-30.
insulinomas: short- and long-termoutcomes after enucleations and 21. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M,
pancreatic resections. Arch Surg 2012;147:261-6. Baum RP, Mittra E, Hobday T, Hendifar A, Oberg K, Lopera Sierra
7. Gaujoux S, Partelli S, Maire F, D’Onofrio M, Larroque B, Tamburrino M, Ruszniewski P, Kwekkeboom D; on behalf of the NETTER-1
D, Sauvanet A, Falconi M, Ruszniewski P. Observational study study group. 177-Lu-Dotatate significantly improves progression-
of natural history of small sporadic non functioning pancreatic free survival in patients with midgut neuroendocrine tumours: results
neuroendocrine tumors. J Clin Endocrinol Metab 2013;98:4784-9. of the phase III NETTER-1 trial. Late Breaking Abstract (6LBA) at
8. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, the 2015 European Cancer Congress (ECC), Vienna, Austria.
Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J, Delle 22. Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC,
Fave GF, O’Toole D; Frascati Consensus Conference participants. Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano
Consensus guidelines for the management of patients with liver A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M,
metastases from digestive (neuro)endocrine tumors: foregut, midgut, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana
hindgut, and unknown primary. Neuroendocrinology 2008;87:47-62. A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia
9. Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave M, Berruti A, Colao A, Falconi M, Delle Fave G. Real-world study
G, Falconi M. Role of resection of the primary pancreatic of everolimus in advanced progressive neuroendocrine tumors.
neuroendocrine tumour only in patients with unresectable Oncologist 2014;19:966-74.
metastatic liver disease: a systematic review. Neuroendocrinology 23. Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G,
2011;93:223-9. Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada
10. Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, F. Everolimus in combination with octreotidelong-actingrepeatable
Tamburrino D, Keck T, Caplin ME, Bartsch D, Thirlwell C, Fusai in a first-line setting for patients with neuroendocrine tumors: an
G, Falconi M. Long-term outcomes of surgical management ITMO group study. Cancer 2014:120:2457-63.
of pancreatic neuroendocrine tumors with synchronous liver 24. Kamp K, Gumz B, Feelders RA, Kwekkeboom DJ, Kaltsas G,
metastases. Neuroendocrinology 2015;102:68-76. Costa FP, de Herder WW. Safety and efficacy of everolimus in
11. Ahlman H, Wängberg B, Jansson S, Friman S, Olausson M, gastrointestinal and pancreatic neuroendocrine tumorsafter (177)
Tylén U, Nilsson O. Interventional treatment of gastrointestinal Lu-octreotate. Endocr Relat Cancer 2013;20:825-31.
neuroendocrine tumours. Digestion 2000;62 Suppl 1:59-68. 25. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E,
12. Makridis C, Oberg K, Juhlin C, Rastad J, Johansson H, Lörelius Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti
LE, Akerström G. Surgical treatment of mid-gut carcinoid tumors. P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K.
World J Surg 1990;14: 377-83; discussion 384-5. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl
13. Sutton R, Doran HE, Williams EM, Vora J, Vinjamuri S, Evans J Med 2011;364:514-23.
J, Campbell F, Raraty MG, Ghaneh P, Hartley M, Poston GJ, 26. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E,
Neoptolemos JP. Surgery for midgut carcinoid. Endocr Relat Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre
Cancer 2003;10:469-81. N, Sachs C, Valle JW, Delle Fave G, Van Cutsem E, Tesselaar M,
308
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 17, 2016 ¦